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Carcinoma of the prostate is the second most common cause of
cancer-related deaths in males (Tang and Porter 1997). The disease
occurs in 2 phases, with the first phase characterized by the growth
of hormone-dependent tumours which respond to hormone abla-
tion therapy, and in the second phase, usually 2–3 years post-
therapy, the disease re-appears in the form of hormone-insensitive
tumours which are unresponsive to conventional chemotherapy
(Kreis, 1995). Improved understanding of the mechanism(s) by
which hormone-independent prostate tumour cells become res-
istant to death mediated by conventional anti-cancer agents may
provide the basis for the design of new therapeutic approaches to
the treatment of advanced prostate cancer. 
Apoptosis is defined as programmed cell death or cell suicide
and is a process in which the cell actively participates in its own
destruction, under the control of a variety of internal and ex-
ternal signals. The apoptotic cell undergoes several morphological
changes in this complicated pathway to cell death including cyto-
plasmic dehydration and shrinkage, chromatin condensation and
the formation of apoptotic bodies containing chromatin and cyto-
plasm in the final stages (Mundle et al, 1996). Since rates of cell
proliferation relative to cell death are crucial to the homeostasis of
an organism, abnormal apoptotic rates are prevalent in human
diseases, and either a lack of or too much apoptotic death may lead
to cancer or degenerative disease, respectively (Allen et al, 1998). 
Of the proteins and genes involved in the regulation of apop-
tosis, members of the Bcl-2 gene family play a central role in its
inhibition or promotion. In mammalian cells this polypeptide
family comprises several members, some of which suppress cell
death, e.g., Bcl-2 and Bcl-xL while others promote apoptosis, e.g.,
Bax, Bik, Bid and Bak (Kroemer, 1997). Nearly all Bcl-2 fam-
ily member have a membrane-targeting domain at its carboxy
terminus allowing it to attach to mitochondrial, ER and nuclear
membranes (Zhu et al, 1996). Pro-and anti-apoptotic Bcl-2 family
members can form homodimers and heterodimers and the relative
ratios of these dimers are believed to gauge the sensitivity of a cell
towards either survival or apoptosis. Bcl-2 family members share
at least one of the Bcl-2 homology regions 1, 2, 3 and 4 (BH1,
BH2, BH3 and BH4) (Yang and Korsmeyer, 1996) which are
required for dimerization and for regulation of apoptosis (Hirotani
et al, 1999). Truncated forms of pro-apoptotic Bak (Chittenden
et al, 1995) and Bax (Han et al, 1996) consisting only of their BH3
regions have been shown to be sufficient to induce apoptosis and
antagonize the effects of anti-apoptotic members (Zhou et al,
2000). 
In the second phase of prostate cancer apoptosis-resistant clones
appear as a result of genetic alterations (Tang and Porter,
1997). Bcl-2 is commonly overexpressed in a number of cancers,
including hormone-independent prostate carcinoma (Colombel
et al, 1993; Krajewska et al, 1996), and it has been indicated that
androgens promote Bcl-2 expression (Berchem et al, 1995). Also,
prostate cancer patients with an elevated Bcl-2/Bax ratio are asso-
ciated with an increased risk of their cancer failing to respond to
radiotherapy (Mackey et al, 1998). The ability of Bcl-2 to block
apoptosis may be an important factor in the development of this
disease from the hormone-dependent form to the more aggressive
hormone-independent form. 
We hypothesized that the introduction of synthetic BH3
peptides into cells may increase levels of apoptosis in tumour cells
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where pro-apoptotic Bcl-2 family members bind, thus removing
the inhibitory effect on pro-apoptotic family members, leaving
them free to mediate apoptosis. In an attempt to combat the apop-
tosis resistance associated with prostate cancer metastasis, we
chose a model where synthetic peptides from the BH3 domain of
pro-apoptotic Bcl-2 family members were introduced into Bcl-
2-expressing, hormone-independent prostate cells. We demon-
strated that this resulted in the induction of apoptosis and showed
that the probable mode of action of the peptides was through their
modulation of the interactions of Bcl-2 family members such that
the dominant influence on cell fate switched from the anti-apoptotic
to the apoptosis-inducing family members, resulting in cell death. 
MATERIALS AND METHODS 
Tumour cells and culture conditions 
The human hormone-independent cell lines PC-3 and DU145 were
obtained from American Type Culture Collection (Rockville,
MD). Cells were grown in humidified atmosphere at 37˚C in 5%
CO2 and were maintained in culture as adherent cells in RPMI
1640 (Gibco Life Technologies, Paisley, Scotland) containing 10%
FCS (Gibco), L-glutamine and antibiotics. 
Reagents and antibodies 
Peptides (15 amino acids) derived from the BH3 domains of apop-
tosis agonists Bax (native and C->S forms), Bak and Bik (native
and C->S forms) were provided by Biomeasure Inc, MA and stock
solutions in DMSO (BDH Laboratory Supplies, Poole, UK) were
prepared at 10 mg ml–1 and stored at room temperature. 
FITC-conjugated annexin V was purchased from Bender
MedSystems (Vienna, Austria) and propidium iodide (PI) from
Sigma Chemical Co (St Louis, MO). The following antibodies
were used in the immunoblotting experiments; a mouse mono-
clonal anti-human antibody to Bcl-2 (amino acids 41–54 as
immunogen) from Dako (clone 124) (Cambridge, UK), a mouse
monoclonal anti-human antibody to Bak (amino terminal portion)
from Calbiochem (San Diego, CA) and a mouse monoclonal anti-
body to Bax (recombinant human Bax) from Immunotech
(Coulter, Miami, FA). The secondary antibody used for immunoblot-
ting was an anti-mouse IgG (whole molecule) conjugated to HRP
(Dako). Benzyloxycarbonyl-valinyl-alaninyl-aspartyl-(O-methyl)-
fluoromethylketone (z-VAD.fmk) was obtained from Enzyme
Systems  Products (Livermore, CA). 
Transfer of BH3 peptides into cells via electroporation 
PC3 and DU145 cells were harvested during the exponential
growth phase by trypsinization and were resuspended in their orig-
inal media. They were washed in 0.015 M PBS, pH 7.2 (0.14 M
NaCl, 2 mM KCl, 8 mM Na2HPO4 and 1.5 mM NaH2PO4) and
resuspended at a concentration of 0.625 ´ 106 cells ml–1 in PBS.
PBS was found to give optimum results as an electroporation
buffer as compared with HEPES (Gibco) buffer (20 mM) or RPMI
1640, and was used throughout as the standard electroporation
buffer. 0.8 ml of the cell suspension was mixed with the peptides,
allowed to stand at room temperature for 10 min and added to a
disposable 0.4 cm Bio-Rad electroporation cuvette. An equivalent
volume of DMSO was added to a cell suspension without peptide
for use as a control. Electroporation efficiency for each cell line
was initially determined flow cytometrically by uptake of the fluo-
rescent dye, lucifer yellow (Sigma). Electroporation was carried
out in a Gene-Pulser (Bio-Rad) with cells exposed to one pulse.
Following electroporation, cells were allowed to recover by
standing at room temperature for 10 min, then removed from the
electroporation chamber, washed twice in PBS and resuspended in
2 ml of complete RPMI 1640 at 37˚C prior to analysis. 
Detection of apoptosis by FITC-labelled Annexin V
binding 
PC-3 and DU145 cells were incubated for up to 48 hours with BH3
peptides under the usual cell culture conditions. Apoptosis levels
were assessed flow cytometrically in a Becton Dickinson
FACScan by PI uptake and annexin V binding. Annexin V binds to
phosphatidylserine present on the outer leaflet of the plasma
membrane in early apoptotic cells. Viable cells were identified by
their ability to exclude PI. Control and treated cells were washed
once with PBS by centrifugation at 400 g, resuspended in HEPES
buffer (10 mM HEPES-NaOH, pH 7.4, 150 mM NaCl, 5 mM KCl,
12 mM MgCl2 and 1.8 mM CaCl2), incubated with FITC-
conjugated annexin V (1 mg ml–1) (Bender MedSystems) and PI
(10 mg ml–1) (Sigma) for 5 min at room temperature and immedi-
ately analysed by flow cytometry to quantitate annexin V binding 
(FL-1) and PI uptake (FL-2). A minimum of 10 000 events were
analysed for each sample. 
Immunoprecipitation and Western blotting 
PC-3 cells were lysed in 0.2% NP-40 isotonic lysis buffer as previ-
ously described (Oltvai et al, 1993). Immunoprecipitation was
carried out with 300 mg of cell lysate. For immunoprecipitation of
Bcl-2, a mouse monoclonal anti-human Bcl-2 antibody (specific
for Bcl-2 p25) coupled to agarose (Santa Cruz Biotechnology) was
added to each sample. For immunoprecipitation with Bak and Bax,
lysates were precleared with goat anti-mouse IgG agarose (Sigma)
which was removed by centrifugation. Specific antibodies (anti-
Bak or anti-Bax) and goat anti-mouse IgG agarose were used to
capture the immune complexes. Western blot analysis was subse-
quently carried out. 
RESULTS 
Western blot analysis for the expression of Bcl-2 family
members in the PC-3 prostatic carcinoma cell line 
A therapy strategy based on interfering with the molecular interac-
tions of Bcl-2 and its proapoptotic counterparts would require that
the target cells used express the appropriate members of the Bcl-2
family of proteins. Previous studies have shown that PC-3 cells are
positive for several Bcl-2 family member proteins (Haldar et al,
1996; Rokhlin et al, 1997). Cells with high levels of expression of
anti-apoptotic family members, particularly Bcl-2 or Bcl-xL, could
be expected to respond optimally to this mode of therapy. 
We examined by Western blot analysis the presence of Bcl-2
family members in the PC-3 and DU145 cell lines. Analysis
revealed the presence of Bcl-2, Bcl-XL, Bax and Bak in PC-3 cells.
We found that DU145 cells expressed low levels of Bcl-XL and
Bax, but expressed high levels of Bcl-2 and Bak (Figure 1). 
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Introduction of BH3 peptides into prostatic tumour
cells by electroporation induced apoptosis 
Electroporation conditions for PC-3 and DU145 cells were
initially optimized for efficiency of delivery of macromolecules
into the cell by the use of the fluorescent marker lucifer yellow.
Conditions were set at 25 microfarads and 0.6 kV cm–1 for PC-3
cells and at 960 microfarads and 0.15 kV cm–1 for DU145 cells
which gave extensive intracellular delivery at the lowest expense
of viability (≤80%), as assessed by PI uptake. At higher voltages
extensive cell lysis was observed. 
These settings were then used to evaluate the effect of electro-
poration of peptides derived from the BH3 domains of pro-
apoptotic Bcl-2 family members (Table 1) on apoptosis levels of
PC3 and DU145 cells as compared to control cells electroporated
under identical conditions in the absence of peptide. Electroporation
of PC-3 cells with peptides mimicking the BH3 regions of Bak and
Bax (C->S form) resulted in the induction of apoptosis over time
(Figure 2A, B), at a peptide concentration of 50 mg ml–1. At 10 h
cells exhibited apoptotic features which were detected by changes
in PS on the plasma membrane as measured by annexin V uptake,
reaching 40–50% apoptosis 48 h after introduction of the peptides.
Under identical electroporation conditions peptides from the BH3
regions of Bik (native and C->S form) and of Bax showed no
comparable increase in apoptosis in PC-3 cells (Figure 2C).
Apoptosis levels were the same as control levels in cells exposed
to BH3 peptides in the absence of electroporation (Figure 2D),
indicating that intracellular delivery of BH3 peptides was required
for demonstration of the apoptotic effect of BH3 peptides.
Compared to control cells electroporated under identical condi-
tions in the absence of peptide. Expression of Bcl-2 family
members has been previously examined by Western Blot analysis
in the DU145 prostate cell line (Rokhlin et al, 1997) and it has
been shown to express Bcl-XL and Bak. We found that although
DU145 cells express both Bak and Bcl-XL, Bcl-XL is only
expressed in low amounts and it appears that Bcl-2 is the more
important anti-apoptotic family member in these cells (Figure 1).
The effects of electroporation of DU145 cells with the BH3
peptides (derived from Bak and Bax) was also assessed over time
(Figure 2E, F), and results showed that up to 40% apoptosis was
induced after 48 h at a peptide concentration of 50 mg ml–1. 
The caspase inhibitor z-VAD.fmk reduced apoptosis
induced by BH3 peptides to control levels 
While we had already shown that tumour cells underwent changes
in PS on the plasma membrane in response to electroporation of
BH3 peptides, a typical feature of an apoptotic cell, we wished to
further confirm that the effects seen were as a result of apoptosis.
Caspase activation is a key event in the process of apoptosis and
we next assessed whether, by inhibiting caspase activity in PC-3
and DU145 cells, apoptosis was modulated. In order to demon-
strate whether caspases played a role in the apoptotic pathway
mediated by BH3 peptides a broad spectrum peptide inhibitor of
the caspase family, z-VAD.fmk (50 mM), was added to cells just
prior to electroporation with the peptides and apoptosis levels over
time were measured as before by surface expression of FITC-
labelled annexin V. Cells that were treated with peptides in the
presence of z-VAD.fmk had the inhibitor present in the culture
medium throughout the duration of the incubation period. 
As shown in Table 2, addition of z-VAD.fmk to PC-3 and
DU145 cells afforded protection from apoptosis and led to the
abrogation of the apoptotic effects of peptides from the BH3
regions of both Bax and Bak, leaving apoptosis levels equal to
control cells electroporated in the absence of peptide. This result
indicated that apoptosis induced in cells following the introduction
of BH3 peptides by electroporation acted via activation of a z-
VAD.fmk-sensitive agent, presumably one or more members of
the caspase family. 
Also of note in Table 2 is that the peptide from the BH3 region
of Bax which did not induce apoptosis following electroporation
showed was no change in this level of apoptosis upon treatment
with z-VAD.fmk. This result indicated that the inhibitory effect of
z-VAD.fmk is specific for apoptosis induced by peptides from the
BH3 regions of Bak and Bax (C->S form). 
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Figure 1 Expression of various Bcl-2 family members in lysates from PC-3
and DU145 cells. Cellular protein lysates were resolved by 12% SDS-PAGE
under reducing conditions, transferred to nitrocellulose membranes and
detected by the corresponding Abs. Bak (A), Bax (B), Bcl-2 (C) and Bcl-XL
(D) were probed on 4 separate blots as the molecular weights of the Bcl-2
family members were similar. Actin was also probed to ensure equal loading 
Table 1 Peptides derived from BH3 domains 
BH3 domain Sequencea
Bak Ac 74 VGRQLAIIGDDINRR 88 NH2 
Bax Ac 59 LSECLKRIGDELDSN 73 NH2 
Bik Ac 57 LALRLACIGDEMDVS  71 NH2 
Bax (C62->S)b Ac 59 LSESLKRIGDELDSN  73 NH2 
Bik (C63->S)b Ac 57 LALRLASIGDEMDVS  71 NH2 
aSequences are shown using the single letter code for amino acids. Numbers
refer to the position of the terminal amino acids of the peptide in the parent
protein. bWe found that native Bax and Bik peptides did not induce any
apoptosis in the cells. We discovered that the cysteine residues in the
sequences were unstable and were oxidised, producing unactive peptides.
By creating the Bax(C62->S) and Bik (C63->S) peptides we found that the
peptides were more stable in storage and the Bax (C62->S) peptide was
capable of inducing apoptosis in both PC-3 cells and DU145 cells. Immunoprecipitation studies showed no evidence of
heterodimerization between Bcl-2 and Bax 
Pro- and anti-apoptotic Bcl-2 family members can heterodimerize
and seemingly titrate one another’s function (Adams and Cory,
1998). Bcl-2 and Bax have been shown to heterodimerize in
several cell lines (Yin et al, 1994; Otter et al, 1998) and both
proteins were found to be present in PC-3 cells. Following the
finding that a peptide derived from the BH3 region of Bax medi-
ated apoptosis in PC-3 cells we next assessed whether this was
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Figure 2 The effects of BH3 peptides on apoptosis levels in prostate cancer cell lines. Analysis of the levels of apoptosis over time of PC-3 cells after
electroporation with peptides derived from (A) the BH3 domain of Bak (50 mg ml–1) and (B) the BH3 domain of Bax(C->S) (50 mg ml–1), (C) the BH3 domains of
Bax and Bik (native and C->S forms) (50 mg ml–1) at T = 18 h, (D) shows the levels of apoptosis at T = 24 h in cells exposed to BH3 peptides in the absence
of electroporation and finally the levels of apoptosis over time of DU145 cells after electroporation with peptides derived from the BH3 domains of (E) Bak
(50 mg ml–1) and (F) Bax (C->S) (50 mg ml–1). Cells (0.5 ´ 106) were electroporated with or without BH3 peptides and apoptosis was assessed immediately
(T = 0 h) or cells were then incubated in RPMI1640 at 37˚C and harvested 6 h, 10 h, 24 h and 48 h after electroporation. The data are representative of at least
3 separate experiments. Apoptosis was determined by staining cells with FITC-labelled annexin V (FL1) and PI (FL2). Apoptosis was assayed by FACS
analysis and the percentage of cells undergoing apoptosis (represented in the lower right hand quadrants in C and D) were measured for up to 48 h 
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associated with altered interactions between Bcl-2 and Bax
in these cells. We first determined whether heterodimerization
between Bcl-2 and Bax could be detected in the PC-3 cell line by
immunoprecipitation studies. Results showed that, while PC-3
cells immunoprecipitated with an anti-Bax antibody yielded large
amounts of Bax protein, probing this immunoprecipitated Bax
with an anti-Bcl-2 antibody showed that the 2 proteins did not
appear to co-immunoprecipitate (Figure 3a). Based on this and
subsequent experimental observations we concluded that there
was no detectable heterodimerization of Bcl-2 and Bax proteins in
PC-3 cells. 
Immunoprecipitation studies showed
heterodimerization between Bcl-2 and Bak and
evidence of modulation of this interaction by BH3
peptides 
Since the peptide mimicking the BH3 region of Bak was found to
induce apoptosis in PC-3 cells we next assessed by co-
immunoprecipitation studies whether there was an association
between Bcl-2 and Bak in unstimulated, control cells and whether the
introduction by electroporation of BH3 peptides into the cytoplasm
of PC-3 cells antagonised the association between Bcl-2 and Bak.
Immunoprecipitation studies were carried out on lysates from
untreated PC-3 cells and cells electroporated with peptides derived
from the BH3 regions of Bak and Bax. Figure 3B demonstrates that
the level of Bak immunoprecipitated from untreated cells and cells
electroporated with BH3 peptides are comparable. However, when
the same samples were probed to assess whether Bcl-2 co-immuno-
precipitated with Bak, it was found that the levels of Bcl-2 which
were associated with Bak varied greatly between the 3 groups.
Untreated cells showed a strong association between Bak and Bcl-2,
indicating that these proteins heterodimerize in the control state.
Levels of Bcl-2 found to co-immunoprecipitate with Bak were
greatly reduced in PC-3 cells electroporated with peptide from the
BH3 region of Bak compared with control cells, while treatment
with peptide from the BH3 region of Bax appeared to abrogate all
Bak/Bcl-2 interactions. This result demonstrated that the introduc-
tion via electroporation of a peptide derived from the BH3 region of
Bak into PC-3 cells strongly inhibited interactions between Bak and
Bcl-2 compared with control cells and that this interaction was
completely abrogated following the introduction of a peptide
derived from the BH3 region of Bax. 
DISCUSSION 
The purpose of this study was to determine whether apoptosis
could be induced in an androgen-independent prostate carcinoma
cell line by introducing synthetic peptides derived from the BH3
regions of pro-apoptotic Bcl-2 family members into the cells.
Prostate cancer progression and metastasis is associated with over-
expression of Bcl-2 and the acquisition of an androgen-insensitive
phenotype that is resistant to current therapies (McDonnell et al,
1992), suggesting that apoptosis resistance may be a cause of drug
resistance. 
Here we have shown that apoptosis was induced in prostate
carcinoma cell lines by introducing peptides from the BH3 regions
of Bax and Bak and that, when Bak was immunoprecipitated from
lysates of cells treated with a peptide mimicking the BH3 region
of Bak, a significant reduction in the amount of Bcl-2 co-
immunoprecipitating with Bak was detected. This indicated the like-
lihood that, in this system, Bcl-2/Bak heterodimers were required
for the potent death suppressor activity of Bcl-2 and that by intro-
ducing BH3 peptides into prostate tumour targets this suppression
could be attenuated. The resulting increase in levels of apoptosis
could be due to the release of Bax or Bak-like proteins from the
inhibitory influence of Bcl-2-like proteins, resulting in cell death.
Table 2 Effects of Z-VAD.fmk on levels of apoptosis in PC-3 and DU145
cells following electroporation with BH3 peptides 
PC-3 DU145 
BH3 domain % Apoptosisa
Control 10.1 ± 1.00 6.4 ± 3.74 
Bax(C62->S) BH3 domain (50 mg ml-1) 19.2 ± 1.80 20.2 ± 1.08 
Bax(C62->S) BH3 domain + Z-VAD 9.3 ± 0.40 8.4 ± 1.44 
Bak BH3 domain (50 mg ml-1) 23.1 ± 5.03 25.5 ± 4.16 
Bak BH3 domain + Z-VAD 12.9 ± 0.60 11.2 ± 1.69 
Bax BH3 domain (50 mg ml-1) 11.1 ± 0.85 11.6 ± 2.60 
Bax BH3 domain + Z-VAD 11.1 ± 0.55 6.4 ± 0.53 
aCells were electroporated with peptides from the BH3 regions of Bax and
Bak, incubated with or without ZVAD.fmk (50 mM) for 10 h and apoptosis was
measured flow cytometrically by assessment of uptake of FITC-labelled
annexin V and PI. Results show the mean of 3 separate experiments ± SD. 
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Figure 3 Immunoprecipitation of PC-3 cells to look for Bax/Bcl-2 and
Bak/Bcl-2 heterodimerization. (A) Cells were immunoprecipitated with anti-
Bax mAb, divided into equal portions and loaded onto duplicate SDS-PAGE
gels and immunoblotted with anti-Bcl-2 and anti-Bax antibodies as detailed in
the Materials and Methods section. (B) Immunoprecipitation of PC-3 cells
following electroporation of BH3 peptides. Cells were electroporated with
BH3 peptides (50 mg ml–1), whole cell lysates were extracted and 300 mg of
lysates were immunoprecipitated with anti-Bak mAb. The reconstituted
immune complexes were divided equally and loaded onto duplicate 10%
SDS-PAGE gels and immunoblotted with either anti-Bak or anti-Bcl-2 mAb120 NM Finnegan et al
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The BH3 regions of Bak and Bax are required for promoting
cell death and for binding to apoptotic inhibitors (Chittenden et al,
1995; Zha et al, 1996), however, evidence suggests that apoptosis
antagonists of the Bcl-2 family protect cells from death by binding
to and neutralizing death agonists (Yin et al, 1994; Allen et al,
1998). Mutations within the BH domains of Bcl-2 and Bcl-xL can
disrupt heterodimerization with proapoptotic family members (Yin
et al, 1994) and it has previously been shown that a 50% reduction
in the formation of Bcl-2/Bax heterodimers can drive cells
towards apoptosis (Yang et al, 1995; Haldar et al, 1996). Thus, our
hypothesis was that peptides corresponding to the BH3 region 
of pro-apoptotic Bcl-2 family members could interfere with
protein–protein interactions between Bcl-2 family members such
that the dominant influence on cell fate was switched from the
anti-apoptotic to the apoptosis-inducing family members. 
We have shown that treatment of cells with peptides mimicking
the BH3 region of Bax resulted in the abrogation of Bak/Bcl-2
interactions. Bak and Bax share significant sequence homology
(Diaz et al, 1997; Kroemer, 1997) and they share common targets,
e.g., the Bcl-2 protein. While it is possible that the peptides bind
preferentially to the proapoptotic Bcl-2 family members we feel
that this is unlikely in the context of our data. Our results indicated
that peptides from the BH3 regions of both Bax and Bak bound
with Bcl-2, displacing Bcl-2/Bak heterodimer formation, and
implied that the peptide from the BH3 region of Bax had a higher
affinity for heterodimerization with Bcl-2 than the peptide from
the BH3 domain of Bak. Pro-apoptotic Bad has been shown to
oppose Bcl-xL-mediated survival and accelerate cell death by
displacing Bax from Bcl-xL (Yang et al, 1995). In a similar fashion,
BH3 peptides may have a high affinity for heterodimerization with
Bcl-2 and consequently displace Bak/Bcl-2 heterodimers. Peptides
derived from the BH3 domains of Bak and Bax block both Bcl-
2/Bax and Bcl-2/Bcl-2 binding (Diaz et al, 1997). It thus appears
that many of the Bcl-2 family members share common binding
motifs that are responsible for homodimerization and heterodimer-
ization and it is likely that the BH3 peptides can modulate interac-
tions involving other anti-apoptotic family members, e.g., Bcl-xL,
and contribute to the apoptotic effect seen here. 
It has previously been shown that pro-apoptotic Bak and Bik
play a role in the initiation of the apoptotic programme and that 
z-VAD.fmk attenuated this cell death, implying that these Bcl-2
family members trigger apoptosis by activation of caspases (Orth
et al, 1997). When we investigated the ability of the broad speci-
ficity caspase inhibitor, z-VAD.fmk, to inhibit apoptosis triggered
by BH3 peptides in PC-3 cells we found that, in the case of
peptides resembling the BH3 regions of Bak and Bax, z-VAD.fmk
provided complete protection from apoptosis. Thus, if the apop-
tosis induced by BH3 peptides is mediated by the pro-apoptotic
members of the Bcl-2 family such as Bak, then this result implies
that they mediate apoptosis through activation of a z-VAD.fmk-
sensitive regulator, which indicates a downstream effector role
for caspases. Pan et al have shown that Bcl-XL and not Bcl-2
sequesters APAF-1, a vital component of the Caspase 9 apopto-
some (Pan et al, 1998). Thus the Bcl-2 family members inhibit
apoptosis through a variety of mechanisms. Further study would
be required to delineate the apoptotic pathway following incuba-
tion of Prostate cancer cells with BH3 peptides. The actual
caspases involved remains to be elucidated but the mechanism is
most likely mediated through caspase 9 activation and subsequent
caspase 3 activation (Jurgensmeier et al, 1998). Similar to reports by
other authors who found that Bax-mediated release of cytochrome c
was not accompanied by mitochondrial permeability transition
(Jurgensmeier et al, 1998), we did not see changes in mitochon-
drial depolarization following introduction of BH3 peptides (data
not shown). 
Our results are in agreement with the hypothesis that BH3 peptides
interact with the site on Bcl-2 where pro-apoptotic proteins bind, thus
preventing the subsequent binding of BH3 domains of Bak or Bax-
like proteins to these sites and resulting inthe liberation of Bak/Bax to
mediate cell death as homodimers/monomers. In conclusion, we have
shown that peptides mimicking the BH3 domains of pro-apoptotic
Bcl-2 family members Bak and Bax-induced apoptosis in prostate
carcinoma cell lines via a z-VAD.fmk-inhibitable mechanism. While
the BH3 peptides themselves are not cell permenant, we are
currently developing an assay to identify non-peptidic compounds
which mimic the properties of these peptides. These results point
to the potential use of such agents as a new therapeutic strategy for
the treatment of diseases associated with resistance to apoptosis. It
would be necessary to establish whether the anti-apoptotic effects of
these compounds are restricted to prostate tumour cells by examining
their efficacy in the treatment of other human neoplasms. BH3
peptide therapy may have a distinct advantage over current treatment
regimens in that cells in which apoptosis is suppressed by elevated
levels of anti-apoptotic Bcl-2 family members are selectively killed.
However, in order to establish the clinical relevance of these
compounds, their efficacy would need to be compared with the
efficacy of other clinically relevant treatment regimens that induce
apoptosis in their tumour targets, such as chemotherapeutic agents
and radiation. 
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